- PreveCeutical was recently featured in an interview by Proactive Investors
- The company is currently developing its Sol-gel drug delivery platform for delivery of cannabinoids
- Sol-gel technology is paving the way for direct nose-to-brain drug delivery
Innovative health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was recently featured by Proactive Investors in a “Corporate News Update” regarding the company’s potentially game-changing Sol-gel drug delivery platform (http://nnw.fm/TyU8k). The company earlier provided a written press release updating the Sol-gel program (http://nnw.fm/86uqL).
Sol-gel, a nickname for soluble gel, is taken through nasal (systemic) administration and quickly gels once it comes in contact with the mucosal tissue, paving the way for direct nose-to-brain delivery of drugs and…
More from NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
New York, New York